Cingulate Inc.

NASDAQ:CING

Biotechnology

Healthcare
$5.11 -0.95%

-$0.05 today

Market cap
$76.46M
Beta
-0.91
P/E (TTM)
-1.0
EPS (TTM)
-$5.10
52W Low $3.16High $11.89

Volume 0.95M

Average 0.46M

CING Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Cingulate Inc.NASDAQ: CING

Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Free cash flow growth accelerates

Q1 FY2026 free cash flow of $6.97M (cash outflow) rose 51.3% year over year, ahead of the +36.9% change in trailing-twelve-month free cash flow. Sequentially, it rose 85.8% from the prior quarter. Over 3 fiscal years it compounded at +2.8% a year.

Context

  • Free cash flow grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +51.3% holds above the trailing-twelve-month pace of +36.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$6.97M+85.8% QoQ
Last fiscal yearDec 2025
-$17.41M-6.7% YoY
LTMMar 2026
-$19.77M+36.9% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+51.3%——
1 year-6.7%——
3-year CAGR+2.8%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(17.41M) USD
Year-over-year change
+6.7%

Free Cash Flow vs competitors

How CING compares with its peers on the latest reported figures

  • CING's LTM Mar 2026 free cash flow of $19.77M is the largest of the 2 companies compared; the peer median is $4.36M.
  • Its year-over-year change of +36.9% is the lowest of 2, against a peer median of +48.1%.
  • Over three fiscal years its annual growth of +2.8% compares with a peer median of -12.7%.
CING Competitors Peer median
Free Cash Flow for CING and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CINGCingulate Inc.LTM Mar 2026$19.77M +36.9%+2.8%—
LIXTLixte Biotechnology Holdings, Inc.LTM Mar 2026$4.36M +48.1%-12.7%—
Peer median (excluding CING) $4.36M+48.1%-12.7%—

Competitors are the stored peer set for CING. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.71M)(17.68M)(23.53M)(15.55M)(22.45M)
Depreciation & Amortization708.32K394.01K582.92K653.09K540.89K
Deferred Income Tax(16.26M)(797.96K)000
Stock-Based Compensation12.78M800.8K812.67K995.48K0
Change in Working Capital(3.21M)598.62K7.1M(4.55M)830.85K
Accounts Receivables(1.86M)1.25M219.81K(11.7K)18.31K
Inventory0(1.25M)000
Accounts Payables0791.01K000
Other Working Capital(1.35M)(192.39K)6.89M(4.54M)812.54K
Other Non-Cash Items16.26M797.96K003.83M
Operating Cash Flow(10.43M)(15.88M)(15.03M)(18.45M)(17.25M)
Capital Expenditures(814.74K)(153.42K)(224.1K)(211.8K)(162.14K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments0933000
Other Investing Activities0(165)00138
Investing Cash Flow(814.74K)(152.65K)(224.1K)(211.8K)(162K)
Debt Repayment(936.59K)4.98M2.98M4.95M6M
Common Stock Issued20.37M(85.92K)6.97M25.88M10.15M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7.1M000(382)
Financing Cash Flow26.54M4.9M9.95M30.82M16.15M
Effect of Forex Changes00000
Net Change in Cash15.3M(11.14M)(5.3M)12.16M(1.26M)
Free Cash Flow(11.25M)(16.04M)(15.26M)(18.66M)(17.41M)

Cingulate Inc.

NASDAQ:CING

Intrinsic Alpha fair value

Locked

Current Price

$5.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.